small molecule

VYNDAMAX

TAFAMIDIS

Loss of exclusivityAugust 2035latest FDA-listed patent expiry

CompanyFOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC

Drug detail

Brand name	VYNDAMAX
Active ingredient	TAFAMIDIS
Strength	61MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	May 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
9770441	August 2035	substance, product
7214696	December 2026	use U-2524
7214695	December 2026	substance, product

Regulatory exclusivity

Code	Expires
ODE-237	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC